IVF Fit AS™ vision is to personalise solutions for assisted reproductive techniques (ART), commonly known as in vitro fertilisation treatment (IVF). IVF Fit™ is a startup that will target the European fertility market with its first product, OptimOva™, an in vitro diagnostics medical device kit which fine tunes the clinician’s hormone dose estimation.
Ninety-one percent of women who undergo IVF receive stimulating hormones to achieve a pregnancy. IVF treatment success is based on the production of multiple egg cells through a daily injection of stimulating hormones. Estimation of hormone dosage is a key challenge since the dose needs to be finely adjusted to avoid too low or high hormone response. Currently, 20 – 23% of treatments are cancelled due to undesirable hormone responses. In Europe, this means almost 200 000 treatments per year are cancelled annually.
Fertility doctors are in need of tools that help them estimate the optimal hormone dose for treatment. Currently, no method for personalised hormone dosage exists. Therefore, indirect methods which are based on patients’s clinical history, infertility cause, hormonal profiles and physician’s clinical experience are commonly employed. OptimOva™ utilises a cell biomarker value which is unique for each patient, thus making IVF treatment more precise and optimised.